Commentary

Video

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

Author(s):

Prithviraj Bose, MD,Javier Pinilla, MD, PhD

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Related Videos
Craig Eckfeldt, MD
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Related Content
Naseema Gangat, MBBS, of Mayo Clinic
January 10th 2025

Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Duvelisib Plus Venetoclax in Chronic Lymphocytic Leukemia | Image Credit: © LASZLO– stock.adobe.com
January 9th 2025

Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

lertsakwiman – stock.adobe.com
January 8th 2025

China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
January 8th 2025

Fixed-Duration Zanubrutinib/Venetoclax Shows Efficacy in R/R Chronic Lymphocytic Leukemia